Slide 1: Phase 2 study of BHB/HRS-1893 in symptomatic non-obstructive HCM
Phase 2 randomized, double-blind, placebo- controlled study to evaluate BHB/HRS-1893 in adults with symptomatic non-obstructive hypertrophic cardiomyopathy Limei Wang, MD 11 May 2026
Slide 2: Disclosures
Disclosures Limei Wang, M.D. – Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China This study and presentation were funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Braveheart
Slide 3: Background
Background • BHB/HRS-1893 is an investigational selective, reversible, small-molecule cardiac myosin inhibitor (CMI) engineered for rapid onset of action, minimal impact on LVEF, and ease of use. • CMIs have improved the management of obstructive HCM and may hold promise as an effective and disease-
Slide 4: Study Design
Study Design • This study enrolled adult nHCM patients with: LVEF ≥60%, NYHA class II-III, resting and Valsalva LVOT-G <30 mmHg at screening, maximal wall thickness ≥15 mm or ≥13 mm with family history of HCM, and KCCQ-CSS ≥30 to ≤85. Design Key Endpoints • Primary endpoint: Safety; LVEF < 50% Low-d
Slide 5: Baseline characteristics
Baseline characteristics BHB-1893 Low-dose BHB-1893 High-dose Characteristic Placebo (N=28) group (N=28) group (N=28) Age (years) 44.5 (11.0) 51.0 (12.0) 47.3 (14.6) Sex: Female 14 (50.0%) 8 (28.6%) 9 (32.1%) BMI (kg/m2) 25.3 (3.87) 25.0 (3.39) 24.6 (3.54) LVEF (%) 68.2 (3.97) 68.2 (4.14) 68.0 (4.21
Slide 6: Distribution of dose levels indicated most patients titrated to highest dose available
Distribution of dose levels indicated most patients titrated to highest dose available BHB-1893 Low-dose BHB-1893 High-dose Last Dose (mg) BHB-1893 Total (N=56) Placebo (N=28) (N=28) (N=28) 20 mg BID 1 (3.6%) 1 (3.6%) 2 (3.6%) 0 (0.0%) 40 mg BID 27 (96.4%) 7 (25.0%) 34 (60.7%) 15 (53.6%) 60 mg BID N
Slide 7: NT-proBNP fell rapidly, deeply, and durably
NT-proBNP, a key biomarker of heart failure, fell rapidly, deeply, and durably Geometric mean NT-proBNP 2000 washout 1500 68% (pg/mL) Drop from baseline in high 1000 dose group 500 0 42% 0 50 100 of patients at 60 mg below 125 pg/mL* Placebo Days Low Dose High Dose Geo metric mean and SE; n≥ 27 (D 0
Slide 8: cTnI levels fell rapidly and low levels were sustained
cTnI levels fell rapidly and low levels were sustained, indicating reduction in heart tissue injury 1.5 washout geometric mean ratio 1.0 60% Hs-cTnI decrease from baseline in high dose 0.5 group 0.0 0 50 100 Placebo Low Dose Days High Dose Geometric mean and SE; n ≥2 7 (D 0 to D84); Hs-cTnI: high s
Slide 9: Myocardial relaxation improved with BHB/HRS-1893
Myocardial relaxation improved with BHB/HRS-1893 Early diastolic relaxation improved Velocities moved from abnormal toward normal 10 15 11.2 7.3 septal e' (cm/s) lateral e' (cm/s) 8 normal 5.5 10 normal 6 7.8 4 5 BL D84 BL D84 HD HD Data presented as mean (SEM); **: p<0.01, ***: p<0.001
Slide 10: Hemodynamic benefit observed, with left atrial volume normalizing
Hemodynamic benefit observed with BHB/HRS-1893, with left atrial volume normalizing 50 41.4 LAVI (mL/m2) 34.3 40 normal 30 BL D84 Observed normalization of left atrial volume index suggests the atrium is no longer pressure-overloaded Data pres ented as mean (SEM); n.s.: n ot significant, *: p <0.05
Slide 11: Left ventricular mass and wall thickness decreased
Left ventricular mass and wall thickness decreased showing structural reverse remodeling in the absence of outflow tract obstruction Data pres ented as mean (SEM); n.s.: not significant, *: p<0.05 , **: p< 0.01; LVMI = left ventricular mass index; LVW T = left ventricular wall thickness
Slide 12: Dose-dependent, placebo-adjusted improvement in KCCQ-CSS
BHB/HRS-1893 demonstrated a dose-dependent, placebo-adjusted, mean improvement in KCCQ-CSS Δ KCCQ-CSS 25 Placebo-adjusted 20 18 increase of +5.5 pts 15 12 15 10 52% of high dose group 5 reported symptom o improvement in the ≥ 20 pt eb LD H D a c category Pl KCCQ-CSS = Kansas City Clinical Questionna
Slide 13: Placebo-adjusted improvement in pVO2 after 12 weeks
BHB/HRS-1893 demonstrated a placebo-adjusted improvement in pVO2 after 12 weeks of treatment Placebo-adjusted Placebo-adjusted +0.5 mL/min/kg 55% +0.9 mL/min/kg mean improvement in of patients in high dose pVO2 in high dose group achieved mean improvement in group, patients ≥1.5 mL/min/kg receiving
Slide 14: Safety and tolerability consistent with prior studies
Safety and tolerability were generally consistent with prior studies of BHB/HRS-1893 • There were no serious AEs or AEs leading to treatment interruption, discontinuation, or death • LVEF<50%: LVEF 46% to 49% all returned to normal with dose reduction BHB/HRS-1893 BHB/HRS-1893 BHB/HRS-1893 Placebo L
Slide 15: Conclusions
Conclusions • Rapid and sustained improvement in clinically relevant biomarkers of diastolic wall stress and microvascular ischemia, NT-proBNP and cTnI, respectively, was observed. • Dose-dependent cardiac functional and structural data suggest disease-modifying profile: • Improvements in diastolic
Slide 16: Acknowledgements
Acknowledgements • All patients and their families • All investigators and research personnel who conducted this trial • Study sponsor: Jiangsu Hengrui Pharmaceuticals Co., Ltd., China • Braveheart Bio, Inc.